- prompt: cohort
  question: |
    Are there multiple cohorts specified in the eligibility criteria for the clinical cancer trial protocol in the attached file? If so, please specify them; e.g., 
    ANSWER: [[Cohort 1]] AND [[Cohort 2]] AND [[Cohort 3]]
    If not, say ANSWER:[[NO]]

- prompt: organ
  question: |
    Based on the eligibility criteria for {cohort} in the attached file, what are the primary organs that the cancer originated from? Please provide the source text portion that your answer is based on. If it is a metastatic cancer and the primary organ was not specified, say ANSWER: [[NOT SPECIFIED]].
    First, please specify the source text that your answer is based on. Then, specify only the name of each primary organ in your ANSWER within double-square brackets without further details.

    Examples:

    SOURCE-TEXT: Patients must have undergone complete surgical resection of their stage IIA, IIB, IIIA, or IIIB non-squamous or squamous NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins.
    ANSWER: [[Lung]]

    SOURCE-TEXT: Metastatic melanoma or non-squamous NSCLC with untreated brain metastases
    ANSWER: [[Skin]] OR [[Lung]]

    SOURCE-TEXT: Metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy
    ANSWER: [[Breast]]

    SOURCE-TEXT: Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology that has relapsed or progressed
    ANSWER: [[Lung]]

    SOURCE-TEXT: Histologically or cytologically-documented, advanced solid tumor of one of the following types: Anal Squamous Cell Carcinoma, Biliary Adenocarcinoma (gallbladder or biliary tree), Neuroendocrine Tumors (lung, appendix, small intestine, colon, rectum, pancreas), Endometrial Carcinoma, Cervical Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Small Cell Lung Carcinoma, Mesothelioma, Thyroid Carcinoma, Salivary Gland Carcinoma
    ANSWER: [[Anus]] OR [[Gallbladder]] OR [[Biliary Tree]] OR [[Lung]] OR [[Appendix]] OR [[Small Intestine]] OR [[Colon]] OR [[Rectum]] OR [[Pancreas]] OR [[Endometrium]] OR [[Cervix]] OR [[Vulva]] OR [[Thyroid]] OR [[Salivary Gland]]

- prompt: organ_confirmation
  question: |
    Please confirm that {organ} is the primary organ that cancer originated from. If affirmative, please say,
    ANSWER: [[YES]]. Otherwise, provide the name of the organs in the ANSWER.

- prompt: location
  question: |
    If particular locations for the primary tumor of {organ} are specified in the inclusion criteria of the attached file, please specify them in your ANSWER after providing the SOURCE-TEXT that your answer is based; otherwise, say, ANSWER: [[NOT SPECIFIED]]

- prompt: cell_type
  question: |
    What cell types of {organ} cancer are required in the inclusion criteria of the attached file. If multiple cell types are mentioned, please specify all of them. If no cell type is mentioned, please say, ANSWER: [[NOT SPECIFIED]].

- prompt: cell_morphology
  question: |
    Is there any mention of required cell morphology specifications in the inclusion criteria for {organ} {cell_type} in the attached protocol? If not, please indicate with ANSWER: [[NO]]. If there are, please provide the SOURCE-TEXT before answering.

- prompt: lymph_node_metastasis
  question: |
    Please indicate whether there is any mention of lymph node metastasis in the attached protocol. If not, say, "ANSWER: [[NOT SPECIFIED]]". If yes, please provide the required MIN and MAX number of nodes involved. If lymph node metastasis should not be present, indicate "ANSWER: [[MAX = 0]]". If there is only a lower or upper limit, indicate only the MIN or MAX value, respectively.

- prompt: organ_metastasis
  question: |
    Please indicate whether there is any mention of organ metastasis in the attached protocol. If not, say, "ANSWER: [[NOT SPECIFIED]]." If yes, please provide the required organs involved. If organ metastasis should not be present, indicate "ANSWER: [[NONE]]." Please provide the SOURCE-TEXT that your answer is based on.

- prompt: lymph_node_metastasis_confirmation
  question: |
    Please confirm that patients with lymph node metastases should be excluded from the trial based on the attached protocol. Provide the SOURCE-TEXT that your answer is based on before responding. "ANSWER: [[YES]]" for confirmation; otherwise, provide MIN and/or MAX number of required lymph node metastases in your answer.

- prompt: organ_metastasis_confirmation
  question: |
    Please confirm if patients with organ metastases should be excluded from the trial as per the attached protocol? Provide the SOURCE-TEXT that your answer is based on before responding. "ANSWER: [[YES]]" for confirmation; otherwise, specify the affected organs in your answer.

- prompt: metastatic_tumor
  question: |
    Please indicate if the number, size, and the location of metastatic tumors are specified in the attached clinical trial protocol? Please provide the SOURCE-TEXT that your answer is based on before responding.

- prompt: staging
  question: |
    Is the required stage or range of stages for {cell_type} of the {organ} specified? If not, say, "ANSWER: [[NOT SPECIFIED]];" otherwise, provide the SOURCE-TEXT that your answer is based on before responding.

- prompt: staging_confirmation
  question: |
    Confirm that patients are excluded from the trial if the {organ} cancer stage is below or beyond {staging}. Say, "ANSWER: [[YES]] to confirm; otherwise, correct the statement after the providing the SOURCE-TEXT that your response is based on.

- prompt: biomarker
  question: |
    Are there any required cancer biomarkers? If not specified, say, "ANSWER: [[NOT SPECIFIED]]." If specified, provide the range of the required value for inclusion.
    Examples,

    SOURCE-TEXT: ALK rearrangement identified by next generation (NextGen) sequencing.
    ANSWER: [[ALK rearrangement]]

    SOURCE-TEXT:  translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay;
    ANSWER: [[ALK gene locus translocation]] OR [[ALK gene locus inversion]]

    SOURCE-TEXT: Estrogen receptor (ER) and progesterone receptor (PR) =< 1% by immunohistochemistry
    ANSWER: [[Estrogen receptor =< 1%]]
    ANSWER: [[Progesterone receptor =< 1%]]

    SOURCE-TEXT: Localized adenocarcinoma of the prostate with the following features: Prostate specific antigen (PSA) < 20 ** Patients receiving a 5-alpha reductase inhibitor must have a PSA < 10
    ANSWER: [[Prostate specific antigen < 20 | Patients NOT receiving a 5-alpha reductase inhibitor]] OR [[Prostate specific antigen < 10 | Patients receiving a 5-alpha reductase inhibitor]]
